Cargando…

Detection of epidermal growth factor receptor mutations in peripheral blood circulating tumor DNA in patients with advanced non-small cell lung cancer: A PRISMA-compliant meta-analysis and systematic review

BACKGROUND: The epidermal growth factor receptor (EGFR) mutation status related to the treatment approach for advanced non-small cell lung cancer (NSCLC) patients. This study aimed to evaluate the diagnostic accuracy of peripheral blood circulating tumor DNA (ctDNA) in EGFR mutated advanced NSCLC pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Shunkai, Huang, Rongzhi, Cao, Yunpeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535563/
https://www.ncbi.nlm.nih.gov/pubmed/33019389
http://dx.doi.org/10.1097/MD.0000000000021965
_version_ 1783590429808132096
author Zhou, Shunkai
Huang, Rongzhi
Cao, Yunpeng
author_facet Zhou, Shunkai
Huang, Rongzhi
Cao, Yunpeng
author_sort Zhou, Shunkai
collection PubMed
description BACKGROUND: The epidermal growth factor receptor (EGFR) mutation status related to the treatment approach for advanced non-small cell lung cancer (NSCLC) patients. This study aimed to evaluate the diagnostic accuracy of peripheral blood circulating tumor DNA (ctDNA) in EGFR mutated advanced NSCLC patients. METHOD: The related database was systematically searched with keywords until January 19, 2020. Studies contained the histopathological and cytological advanced NSCLC samples were included, and the diagnostic data were recorded for calculating sensitivity and specificity. I (2) statistics were used for detecting heterogeneity across studies, and the meta-regression was performed to seek the source of heterogeneity. RESULT: A total of 32 studies with 4527 advanced NSCLC patients were included in our meta-analysis. Among them, 87% of the patients were diagnosed as stage IV. The pooled sensitivity of peripheral blood ctDNA was 0.70 (95% CI: 0.63–0.75, I (2) = 81.76) and the pooled specificity was 0.98 (95% CI: 0.96–0.99, I (2) = 88.33). The meta-regression showed that the prospective study design and the ARMS detection method were the main source of heterogeneity for sensitivity (P < .05), and the publication country (Asia or non-Asia) was the main source of heterogeneity for specificity (P < .01). CONCLUSION: ctDNA biopsy has high specificity and diagnostic accuracy in detection of EGFR mutation in advanced NSCLC patients. When the ctDNA gene test result is negative, we should fully consider the risk of missed diagnosis, and further tissue biopsy is still needed to undertake.
format Online
Article
Text
id pubmed-7535563
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-75355632020-10-14 Detection of epidermal growth factor receptor mutations in peripheral blood circulating tumor DNA in patients with advanced non-small cell lung cancer: A PRISMA-compliant meta-analysis and systematic review Zhou, Shunkai Huang, Rongzhi Cao, Yunpeng Medicine (Baltimore) 5700 BACKGROUND: The epidermal growth factor receptor (EGFR) mutation status related to the treatment approach for advanced non-small cell lung cancer (NSCLC) patients. This study aimed to evaluate the diagnostic accuracy of peripheral blood circulating tumor DNA (ctDNA) in EGFR mutated advanced NSCLC patients. METHOD: The related database was systematically searched with keywords until January 19, 2020. Studies contained the histopathological and cytological advanced NSCLC samples were included, and the diagnostic data were recorded for calculating sensitivity and specificity. I (2) statistics were used for detecting heterogeneity across studies, and the meta-regression was performed to seek the source of heterogeneity. RESULT: A total of 32 studies with 4527 advanced NSCLC patients were included in our meta-analysis. Among them, 87% of the patients were diagnosed as stage IV. The pooled sensitivity of peripheral blood ctDNA was 0.70 (95% CI: 0.63–0.75, I (2) = 81.76) and the pooled specificity was 0.98 (95% CI: 0.96–0.99, I (2) = 88.33). The meta-regression showed that the prospective study design and the ARMS detection method were the main source of heterogeneity for sensitivity (P < .05), and the publication country (Asia or non-Asia) was the main source of heterogeneity for specificity (P < .01). CONCLUSION: ctDNA biopsy has high specificity and diagnostic accuracy in detection of EGFR mutation in advanced NSCLC patients. When the ctDNA gene test result is negative, we should fully consider the risk of missed diagnosis, and further tissue biopsy is still needed to undertake. Lippincott Williams & Wilkins 2020-10-02 /pmc/articles/PMC7535563/ /pubmed/33019389 http://dx.doi.org/10.1097/MD.0000000000021965 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 5700
Zhou, Shunkai
Huang, Rongzhi
Cao, Yunpeng
Detection of epidermal growth factor receptor mutations in peripheral blood circulating tumor DNA in patients with advanced non-small cell lung cancer: A PRISMA-compliant meta-analysis and systematic review
title Detection of epidermal growth factor receptor mutations in peripheral blood circulating tumor DNA in patients with advanced non-small cell lung cancer: A PRISMA-compliant meta-analysis and systematic review
title_full Detection of epidermal growth factor receptor mutations in peripheral blood circulating tumor DNA in patients with advanced non-small cell lung cancer: A PRISMA-compliant meta-analysis and systematic review
title_fullStr Detection of epidermal growth factor receptor mutations in peripheral blood circulating tumor DNA in patients with advanced non-small cell lung cancer: A PRISMA-compliant meta-analysis and systematic review
title_full_unstemmed Detection of epidermal growth factor receptor mutations in peripheral blood circulating tumor DNA in patients with advanced non-small cell lung cancer: A PRISMA-compliant meta-analysis and systematic review
title_short Detection of epidermal growth factor receptor mutations in peripheral blood circulating tumor DNA in patients with advanced non-small cell lung cancer: A PRISMA-compliant meta-analysis and systematic review
title_sort detection of epidermal growth factor receptor mutations in peripheral blood circulating tumor dna in patients with advanced non-small cell lung cancer: a prisma-compliant meta-analysis and systematic review
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535563/
https://www.ncbi.nlm.nih.gov/pubmed/33019389
http://dx.doi.org/10.1097/MD.0000000000021965
work_keys_str_mv AT zhoushunkai detectionofepidermalgrowthfactorreceptormutationsinperipheralbloodcirculatingtumordnainpatientswithadvancednonsmallcelllungcanceraprismacompliantmetaanalysisandsystematicreview
AT huangrongzhi detectionofepidermalgrowthfactorreceptormutationsinperipheralbloodcirculatingtumordnainpatientswithadvancednonsmallcelllungcanceraprismacompliantmetaanalysisandsystematicreview
AT caoyunpeng detectionofepidermalgrowthfactorreceptormutationsinperipheralbloodcirculatingtumordnainpatientswithadvancednonsmallcelllungcanceraprismacompliantmetaanalysisandsystematicreview